E

A look at CheckMate-214 in 1L metastatic RCC

A look at the interim results from the BMS CheckMate-214 trial in renal cell carcinoma

August 16, 2017
E

Future of Cancer Immunotherapy Biomarkers

Where is the field of immune biomarkers going beyond PD-L1 in the next few years?

November 27, 2015
E

How do we boost the effectiveness of checkpoint inhibitors?

A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.

November 2, 2015
E

Immunosurveillance, Immunoscore & Personalized Cancer Immunotherapy – an interview with Jérôme Galon

Interview with Dr Jérôme Galon on Immunosurveillance, Immunoscore and Personalized Cancer Immunotherapy.

October 30, 2015
E

Is there a biomarker for cetuximab in colon cancer?

Finding a biomarker for EGFR monoclonal antibodies in colon cancer has proven elusive but things may be a-changin'...

October 22, 2015
E

Why combine radiation with cancer immunotherapy?

Radiation has the potential to generate an immune response that may lead to an abscopal effect when combined with a checkpoint inhibitor.

October 21, 2015
E

New oncology targets emerge from ECC 2015 – Part 1

Some promising new clinical targets emerged at ECC in Vienna, including DLL3 in SCLC, TRK gene rearrangements, Notch3 and PTK7. What did we think of the data and what issues should you look out for?

October 19, 2015
E

Controversies in lung cancer immunotherapy

Should we be using the PDL1 antibody assay to screen patients for therapy with anti-PD1 and PD-L1 checkpoint inhibitors or? How useful is the test? The debate is heating up!

October 26, 2015
E

Where are the breakthroughs coming in Soft Tissue Sarcoma?

Interview at ECC 2015 with Dr George Demetri on new developments in Soft Tissue Sarcoma

October 6, 2015
E

Potential of Checkpoint Inhibitors in Ovarian Cancer

Interview with Dr Nora Disis about the phase 1b trial results for avelumab in ovarian cancer and the challenges of developing these agents in non-hypermutated tumour types

October 5, 2015
E

What’s hot at Day 3 of European Cancer Congress?

Commentary on Day 3 of the European Cancer Congress in Vienna

September 28, 2015
E

ECC Day 2 Highlights – Checkpoints in Lung and Bladder Cancer

Commentary on Day 2 of the European Cancer Congress in Vienna

September 27, 2015
E

ECC Day 1 Highlights – the battle for Advanced Renal Cell Carcinoma

Highlights from Day 1 of the ECC 2015 (ECCO) meeting in Vienna

September 25, 2015
E

ECC Vienna Preview 2 Oral Presentations

What's hot at ECCO 2015 in the oral sessions? An in-depth preview of what we can expect to hear about in Vienna...

September 10, 2015
E

ECC Vienna Preview 1 Late Breaking Abstracts

What's hot in the 2015 ECCO late breaking abstracts in Vienna? Find out here...

September 8, 2015
E

Atezolizumab PDL1 Checkpoint Inhibitor will change Bladder Cancer Treatment

Atezolizumab is expected to change the standard of care for the treatment of metastatic urothelial bladder cancer

September 3, 2015
E

BMS and Exelixis announce new renal cell cancer data

Will checkpoint inhibitors make their mark in renal cell carcinoma and how will they be integrated into a treatment paradigm dominated by VEGF inhibitors?

July 22, 2015